CD274 and esophageal squamous cell carcinoma: The ATTRACTION-3 (8), KEYNOTE-181 (9), ESCORT (10), and ESCORT-1st (28) trials have led to remarkable changes in ESCC patients with the introduction of PD-1/PD-L1 inhibitors.